Latent TB Diagnostics Market Report Now Available — Reveals Why Rising Prevalence and Rapid, Multiplex Testing Are Expanding Options Even as Cost Pressure Squeezes the Market

Dublin, Oct. 23, 2026 -- "Latent TB Diagnostics Market 2025-2029 - Global Market Analysis and Forecasts by Assay, Risk Factor, and Lab/Place, with Executive and Consultant Guides" has been added to ResearchAndMarkets.com's offering.

The latent TB diagnostics market is entering a new phase of growth as emerging technologies, specialized applications and changing competitive dynamics challenge the position of established companies. Once dominated by a limited number of suppliers offering largely standardized products, the market now presents opportunities for diagnostic developers, investors, laboratories and healthcare organizations seeking to capitalize on innovation and rising demand.

The report provides a focused analysis of the global latent TB diagnostics market, including current market conditions, competitive activity and commercial prospects. It identifies the companies establishing strong market positions while examining how new entrants and disruptive diagnostic technologies could reshape the competitive landscape. Readers can assess which organizations are gaining momentum, where competition is intensifying and which market segments offer the strongest revenue potential.

Detailed market forecasts project latent TB diagnostics market size and growth over the next five years. These projections help organizations evaluate future demand, identify attractive opportunities and develop informed business strategies. The analysis also considers the factors influencing market expansion, technology adoption and purchasing decisions, giving stakeholders a clearer view of the issues likely to affect performance during the forecast period.

Growth across the broader TB diagnostics market is creating new commercial possibilities, although the pace of expansion varies by segment. The report highlights areas demonstrating significant growth and evaluates the niche markets that may generate compelling opportunities. This market intelligence can support product development, portfolio planning, partnership strategies, market entry decisions and competitive positioning.

Competitive analysis offers insight into established participants, emerging leaders and companies introducing potentially disruptive solutions. By examining the fundamentals of competition, the report enables readers to compare market positions and understand how innovation may influence future leadership. It also addresses the potential for advanced diagnostic approaches to alter existing commercial models and create new pathways for growth.

Organizations can use the findings to strengthen investment decisions, company valuations and strategic planning. Current market data and forward-looking analysis provide a reliable foundation for assessing commercial potential, evaluating risks and prioritizing resources. Investors can better identify promising market segments, while diagnostic companies can use the research to refine commercialization plans and evaluate competitive threats.

The report is designed for executives, investors, business development teams, product managers, diagnostic manufacturers, laboratory organizations and other stakeholders requiring actionable latent TB diagnostics market intelligence. Its concise assessment of market size, forecasts, competitors, technologies, opportunities and industry outlooks allows decision makers to develop a well-informed perspective without relying on fragmented sources.

Purchasers also receive assistance and access to additional specific data at no extra charge. This support helps organizations address targeted questions, clarify market findings and apply the research to their individual strategic requirements.

With the latent TB diagnostics market evolving rapidly, access to timely data is essential. The report equips stakeholders with the evidence needed to evaluate opportunities, anticipate competitive change and make investment and valuation decisions with greater confidence.

Key Topics Covered:

1 Market Guides
1.1 Situation Analysis
1.2 Guide for Executives and Marketing Staff
1.3 Guide for Investment Analysts and Management Consultants

2 Introduction and Market Definition
2.1 An Overview of TB Diagnostics
2.1.1 The New Antigen Based TBST
2.2 Market Definition
2.2.1 Market Size
2.2.2 Currency
2.2.3 Years
2.2.4 Limitations
2.3 Methodology
2.3.1 Sources
2.3.2 Authors
2.4 Healthcare and the IVD Industry
2.4.1 Global Healthcare Spending
2.4.2 Spending on Diagnostics
2.4.3 Important Role of Insurance for Diagnostics

3 Tuberculosis - Current Science
3.1 What is Tuberculosis?
3.1.1 Causes
3.1.2 Pathogenesis
3.1.3 Prevention
3.1.4 Treatment
3.2 Diagnosis
3.2.1 Active TB
3.2.2 Latent TB
3.3 Prevalence
3.3.1 Impact of COVID on TB Prevalence

4 Industry Overview
4.1 Players in a Dynamic Market
4.1.1 Academic Research Lab
4.1.2 Diagnostic Test Developer
4.1.3 Pharmaceutical/Reagent Supplier
4.1.4 Independent Testing Lab
4.1.5 Public National/regional lab
4.1.6 Hospital lab
4.1.7 Physician Lab
4.1.8 Audit Body
4.1.9 Certification Body

5 Market Trends
5.1 Factors Driving Growth
5.1.1 Increasing Prevalence
5.1.2 Increasing Diagnostic Options
5.1.3 The Aging World
5.1.4 Increased Health Care Spending
5.2 Factors Limiting Growth
5.2.1 The Cost Curve Shrinks the Market
5.2.2 The Diagnostics Dilemma
5.2.3 Adoption Lag and Cost Control
5.3 Diagnostic Technology Development
5.3.1 The Multiplex Opportunity
5.3.2 Shifting Role of Physicians in Diagnosis
5.3.3 Diagnostics Moves Out of the Lab
5.3.4 Rapid Testing Changing Medical Practice
5.3.5 The Next Five Years

6 TB Diagnostics - Recent Developments
6.1 Recent Developments - Importance and How to Use This Section
6.1.1 Importance of These Developments
6.1.2 How to Use This Section
6.2 Danaher, Cepheid Urged to Further Reduce Price of TB Tests
6.3 Co-Diagnostics Submits At-Home PCR System
6.4 Innovation in TB research by Nanopore
6.5 New skin test for latent TB diagnostics
6.6 Latent TB Infection Screening Recommended
6.7 QIAGEN's QuantiFERON-TB Gold Plus gains new CE-marking
6.8 PerkinElmer Hopes to Gain Market Share against Qiagen
6.9 PBD Biotech to Develop TB Blood Test
6.10 WHO Expands Assessment for TB MDx Developers
6.11 Cepheid Omni POC System Falls Off Radar
6.12 Non-Sputum CRISPR-Based TB Test Shows High Sensitivity
6.13 NGeneBio Gets CE Mark for NGS-Based TB Assay
6.14 MDx TB Assay From PBD Biotech Shows Promise
6.15 Minute Molecular Dx to Launch Rapid PCR Test
6.16 Qiagen Next-Gen TB Test Gains Chinese Approval
6.17 FIND Invests $21M to Launch POC MDx Platforms
6.18 Qiagen, DiaSorin Obtain FDA Approval for Latent TB Test
6.19 Oxford Immunotec to Automate Latent TB Test
6.20 LumiraDx Eyes Test Menu Expansion
6.21 BioMerieux Targeting Hospitals With Desktop Latent TB Test

7 Profiles of Key Companies
7.1 AID GmbH
7.2 Beijing Wantai
7.3 bioMerieux Diagnostics
7.4 Boditech Med, Inc
7.5 Endo International
7.6 Erythra
7.7 Generium
7.8 Glory Biotechnologies Corp.
7.9 Lionex Diagnostics & Therapeutics GmbH
7.10 Oxford Immunotec (Perkin Elmer)
7.11 Perkin Elmer
7.12 Qiagen
7.13 R-Biopharm AG
7.14 Sanofi
7.15 SD Biosensor
7.16 Serum Institute of India
7.17 Statens Serum Institut
7.18 Zhifei Longcom

8 Latent TB Global Diagnostic Markets Overview
8.1 Latent TB Diagnostics - Global Market Overview by Country
8.1.1 Table - Global Market by Country
8.1.2 Chart - Global Market by Country
8.2 Global Latent TB Diagnostics Markets Overview by Assay
8.2.1 Table - Global Market by Assay
8.2.2 Chart - Global Market by Assay - Segments Growth
8.2.3 Chart - Global Market by Assay - Share by Year
8.2.4 Chart - Global Market by Assay
8.2.5 Chart - Global Market by Assay - Base Year
8.2.6 Chart - Global Market by Assay - Final Year
8.3 Global Latent TB Diagnostics Markets Overview by Risk Factor
8.3.1 Table - Global Market by Risk Factor
8.3.2 Chart - Global Market by Risk Factor - Segments Growth
8.3.3 Chart - Global Market by Risk Factor - Share by Year
8.3.4 Chart - Global Market by Risk Factor
8.3.5 Chart - Global Market by Risk Factor - Base Year
8.3.6 Chart - Global Market by Risk Factor - Final Year
8.4 Global Latent TB Diagnostics Markets Overview by Lab
8.4.1 Table - Global Market by Lab
8.4.2 Chart - Global Market by Lab - Segments Growth
8.4.3 Chart - Global Market by Lab - Share by Year
8.4.4 Chart - Global Market by Lab
8.4.5 Chart - Global Market by Lab - Base Year
8.4.6 Chart - Global Market by Lab - Final Year

9 Latent TB Diagnostic Market - by Assay
9.1 Latent TB Diagnostic - TST
9.1.1 Table Latent TB Diagnostic TST - by Country
9.1.2 Chart - Latent TB Diagnostic TST Growth
9.2 Latent TB Diagnostic - IGRA
9.2.1 Table Latent TB Diagnostic IGRA - by Country
9.2.2 Chart - Latent TB Diagnostic IGRA Growth
9.3 Latent TB Diagnostic - TBST
9.3.1 Table Latent TB Diagnostic TBST - by Country
9.3.2 Chart - Latent TB Diagnostic - TBST Growth
9.4 Latent TB Diagnostic -Other
9.4.1 Table Latent TB Diagnostic Other - by Country
9.4.2 Chart - Latent TB Diagnostic - Other Growth

10 Global Latent TB Diagnostics Markets - By Risk Factor
10.1 Latent TB Diagnostic - HIV
10.1.1 Table Latent TB Diagnostic HIV - by Country
10.1.2 Chart - Latent TB Diagnostic HIV Growth
10.2 Latent TB Diagnostic - Pediatric
10.2.1 Table Latent TB Diagnostic Pediatric- by Country
10.2.2 Chart - Latent TB Diagnostic Pediatric
10.3 Latent TB Diagnostic - Diabetes
10.3.1 Table Latent TB Diagnostic Diabetes - by Country
10.3.2 Chart - Latent TB Diagnostic - Diabetes Growth
10.4 Latent TB Diagnostic - Immigration
10.4.1 Table Latent TB Diagnostic Immigration - by Country
10.4.2 Chart - Latent TB Diagnostic - Immigration Growth
10.5 Latent TB Diagnostic - Other Risk Factor
10.5.1 Table Latent TB Diagnostic Other Risk Factor - by Country
10.5.2 Chart - Latent TB Diagnostic - Other Risk Factor Growth

11 Global Latent TB Diagnostics Markets - By Lab/Place
11.1 Latent TB Diagnostic - Hospital Lab
11.1.1 Table Latent TB Diagnostic Hospital Lab - by Country
11.1.2 Chart - Latent TB Diagnostic Hospital Lab Growth
11.2 Latent TB Diagnostic - Outpatient Lab
11.2.1 Table Latent TB Diagnostic Outpatient Lab - by Country
11.2.2 Chart - Latent TB Diagnostic Outpatient Lab Growth
11.3 Latent TB Diagnostic - Point of Care
11.3.1 Table Latent TB Diagnostic Point of Care - by Country
11.3.2 Chart - Latent TB Diagnostic Point of Care
11.4 Latent TB Diagnostic - Other Place
11.4.1 Table Latent TB Diagnostic Other Place - by Country
11.4.2 Chart - Latent TB Diagnostic Other Place

12 Appendices
12.1 United States Medicare System: Clinical Laboratory Fees Schedule

List of Tables [22]

List of Figures [30]

Companies Featured

• AID GmbH
• Beijing Wantai
• bioMerieux Diagnostics
• Boditech Med, Inc.
• Co-Diagnostics
• Danaher
• DiaSorin
• Endo International
• Erythra
• Generium
• Glory Biotechnologies Corp.
• Lionex Diagnostics & Therapeutics GmbH
• LumiraDx
• MDxHealth
• Minute Molecular Dx
• Nanopore
• NGeneBio
• Oxford Immunotec (Perkin Elmer)
• PBD Biotech
• Perkin Elmer
• QIAGEN
• Sanofi
• SD Biosensor
• Serum Institute of India
• Statens Serum Institut
• Zhifei Longcom

For more information about this report visit https://www.researchandmarkets.com/r/ftvfg4

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.